NeoGenomics, Inc. (NEO) is a publicly traded Healthcare sector company. As of May 21, 2026, NEO trades at $8.76 with a market cap of $1.09B and a P/E ratio of 0.00. NEO moved +6.08% today. Year to date, NEO is -26.32%; over the trailing twelve months it is +11.39%. Its 52-week range spans $4.72 to $19.12. Analyst consensus is buy with an average price target of $14.94. Rallies surfaces NEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in NEO news today?
NeoGenomics Debuts RaDaR ST Assay for Residual Disease in Breast, Lung, Colorectal Tumors: NeoGenomics has launched RaDaR ST, a next-generation sequencing-based molecular residual disease assay now commercially available for multiple solid tumor types including breast, lung and colorectal cancers. This test provides ultra-sensitive circulating tumor DNA detection post-treatment, expanding the company's oncology diagnostics suite and supporting earlier relapse monitoring.
NeoGenomics Debuts RaDaR ST Assay for Residual Disease in Breast, Lung, Colorectal Tumors: NeoGenomics has launched RaDaR ST, a next-generation sequencing-based molecular residual disease assay now commercially available for multiple solid tumor types including breast, lung and colorectal cancers. This test provides ultra-sensitive circulating tumor DNA detection post-treatment, expanding the company's oncology diagnostics suite and supporting earlier relapse monitoring.
Does Rallies summarize NEO news?
Yes. Rallies summarizes NEO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is NEO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NEO. It does not provide personalized investment advice.
